📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial (2021)

First Author: Adams R

Attributed to: Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.21.01436

PubMed Identifier: 34516759

Publication URI: http://europepmc.org/abstract/MED/34516759

Type: Journal Article/Review

Parent Publication: Journal of Clinical Oncology

Issue: 33

ISSN: 0732-183X